Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo US$ 55M Series A Generation Therapeutics for BleedingThrombosis Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Haemnet","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Hemab Therapeutics

    Menu

    Hemab Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Hemab Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia

              Details:

              HMB-001 is a novel bispecific antibody designed to be the first prophylactic treatment for Glanzmann Thrombasthenia (GT) and other debilitating bleeding disorders

              Lead Product(s): HMB-001

              Therapeutic Area: Rare Diseases and Disorders Product Name: HMB-001

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hemab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders

              Details:

              The Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline evolution.

              Lead Product(s): HMB-001

              Therapeutic Area: Hematology Product Name: HMB-001

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Deep Track Capital

              Deal Size: $135.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing February 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hemab Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders

              Details:

              The in vivo subcutaneously administered single dosages of HMB-001 showed dose-dependent accumulation of endogenous factor VIIa (FVIIa), with durability of effect supporting weekly to once monthly dosing.

              Lead Product(s): HMB-001

              Therapeutic Area: Rare Diseases and Disorders Product Name: HMB-001

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Haemnet

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Hemab Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novo US$ 55M Series A Generation Therapeutics for BleedingThrombosis Disorders

              Details:

              Proceeds from the financing will be used to progress the Company's promising pipeline of monoclonal and bispecific antibody-based therapeutics into later stages of development.

              Lead Product(s): Monoclonal-bispecific Antibody-based Therapeutics

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Novo Nordisk

              Deal Size: $55.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing July 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY